eMedicine Specialties > Ophthalmology > Intraocular Pressure

Glaucoma, Low Tension: Treatment & Medication

Author: Iqbal Ike K Ahmed, MD, FRCSC, Clinical Assistant Professor, Department of Ophthalmology, University of Utah
Coauthor(s): Baseer U Khan, MD, Staff Physician, Department of Ophthalmology, University of Toronto, Canada; Khalid Hasanee, MD, Glaucoma and Anterior Segment Fellow, Department of Ophthalmology, University of Toronto
Contributor Information and Disclosures

Updated: Jun 22, 2006

Treatment

Medical Care

  • The aim of IOP-lowering medications is for a reduction of at least 30%.

Surgical Care

  • Argon laser trabeculoplasty (ALT): This procedure has minimal effects because the IOP is already in the reference range.
  • Selective laser trabeculoplasty (SLT): This procedure is another alternative. SLT targets pigment-producing cells in the trabecular meshwork with less tissue destruction and scarring as compared to ALT.
  • Trabeculectomy: If medical therapy is ineffective, adjunctive antimetabolite therapy likely is needed for postoperative IOP to be in the single digits. Significant risk of hypotony and endophthalmitis exists.

Consultations

  • Neuroophthalmology consult to rule out compressive optic neuropathy (as indicated)

Diet

  • An increase in salt intake may be recommended if the patient's diastolic blood pressure is significantly lower than the systolic blood pressure (ie, >70 mm Hg). However, controversy exists regarding this recommendation. Exercise caution in those patients with vascular or cardiac disease.

Activity

  • No restrictions on activity are indicated.

Medication

The goals of pharmacotherapy are to reduce IOP and morbidity and to prevent complications.

The aim of IOP-lowering medications is for a reduction of at least 30%. Nonselective beta-blockers (eg, timolol maleate, levobunolol) are controversial.

Medications for neuroprotection are as follows:

  • Calcium channel blockers - Less progression
  • Betaxolol - Improved choroidal flow, better visual field preservation
  • Dorzolamide - Increased retinal blood flow velocity in humans
  • Brimonidine - Increased retinal ganglion cell survival in rat optic nerve crush injury

Future medications include the following:

  • N-methyl-D-aspartate (NMDA) receptor antagonist (Memantine) prevents binding of glutamate and resultant calcium influx - Blocks RGC from glutamate toxicity in rats and blocks toxic level of glutamate in vitreous
  • Serotonin S2 receptor antagonist (Naftidrofuryl) - Arteriolar vasodilation, improved blood flow in Raynaud syndrome
  • Glutamate antagonists
  • Monoamine oxidase inhibitors (Deprenyl) - Neuroprotection in rat crush model
  • Neurotrophic factors (Neurotrophins) - Retard apoptosis in cell culture
  • Free radical scavengers - Ginkgo biloba extract scavenges free radicals and nitric oxide, improves blood flow (60-120 mg bid)
  • Cannabinoids (marijuana) - Reduces IOP with NMDA antagonist and antioxidant activity

Alpha2-adrenergic agonists

Decrease IOP pressure by reducing aqueous humor production.


Brimonidine (Alphagan)

Selective alpha2-receptor that reduces aqueous humor formation and may increase uveoscleral outflow or inhibit inflow.

Adult

1 gtt in affected eye(s) tid

Pediatric

Not established

Coadministration with topical beta-blockers may further decrease IOP; tricyclic antidepressants may decrease effects of brimonidine; CNS depressants, such as barbiturates, opiates, and sedatives, may potentiate effects of brimonidine

Documented hypersensitivity; patients receiving MAOI therapy

Pregnancy

B - Usually safe but benefits must outweigh the risks.

Precautions

May exacerbate or precipitate ocular irritation, topical sensitivity, vasovagal attack, and optic nerve ischemia in patients with advanced glaucomatous optic neuropathy

Carbonic anhydrase inhibitors

By slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport, it may inhibit carbonic anhydrase in the ciliary processes of the eye. This effect may decrease aqueous humor secretion, reducing IOP.


Dorzolamide (Trusopt)

Used concomitantly with other topical ophthalmic drug products to lower IOP. If more than 1 ophthalmic drug is being used, administer the drugs at least 10 min apart. Reversibly inhibits carbonic anhydrase, reducing hydrogen ion secretion at renal tubule and increasing renal excretion of sodium, potassium bicarbonate, and water to decrease production of aqueous humor.

Adult

1 gtt in affected eye(s) tid

Pediatric

Not established

Coadministration with high-dose salicylate therapy may increase toxicity; may have additive systemic effects if patient is already on oral carbonic anhydrase inhibitors

Pregnancy

C - Safety for use during pregnancy has not been established.

Precautions

Local ocular adverse effects, primarily conjunctivitis and lid reactions, may occur with chronic administration of dorzolamide; discontinue therapy and evaluate patient before restarting therapy

Beta-adrenergic blockers

The exact mechanism of ocular antihypertensive action is not established, but it appears to be a reduction of aqueous humor production or inhibition of inflow.


Timolol ophthalmic (Timoptic XE, Timoptic, Blocadren)

May reduce elevated and normal IOP with or without glaucoma by inhibiting inflow.

Adult

1 gtt of 0.25% or 0.5% in affected eye(s) bid; if IOP is maintained at satisfactory levels, change dosage to 1 gtt in affected eye(s) qd; if clinical response not adequate, change dosage to 1 gtt of 0.5% solution in affected eye(s) bid; if IOP is still not at satisfactory level, consider concomitant therapy

Pediatric

Administer as in adults

May cause bradycardia and asystole when used in combination with systemic beta-blockers (may cause additive effects)

Documented hypersensitivity; bronchial asthma; sinus bradycardia; second- and third-degree AV block; severe chronic obstructive pulmonary disease; overt cardiac failure; cardiogenic shock

Pregnancy

C - Safety for use during pregnancy has not been established.

Precautions

Product may have sulfites, which may cause allergic-type reactions in susceptible patients; may exacerbate or precipitate heart block, asthma, chronic obstructive pulmonary disease, and mental changes (especially in elderly patients)


Levobunolol (AKBeta, Betagan)

Nonselective beta-adrenergic blocking agent that lowers IOP by reducing aqueous humor production and possibly increasing outflow of aqueous humor.

Adult

0.5% solution: 1-2 gtt in affected eye(s) qd
0.25% solution: 1-2 gtt in affected eye(s) bid
Severe or uncontrolled glaucoma: 0.5% solution bid; closely monitor patient; > 1 gtt (0.5% levobunolol) bid not shown to be more effective; if IOP not at satisfactory level on this regimen, concomitant therapy can be instituted; do not administer 2 or more topical ophthalmic beta-adrenergic blocking agents simultaneously

Pediatric

Not established

May cause bradycardia and asystole when used in combination with systemic beta-blockers (may cause additive effects)

Documented hypersensitivity; bronchial asthma; severe chronic obstructive pulmonary disease; sinus bradycardia; second- and third-degree AV block; overt cardiac failure; cardiogenic shock

Pregnancy

C - Safety for use during pregnancy has not been established.

Precautions

Beta-blockade may potentiate muscle weakness that is consistent with certain myasthenic symptoms (eg, diplopia, ptosis, generalized weakness); product may have sulfites, which may cause allergic-type reactions in certain susceptible persons


Betaxolol (Betoptic)

Indicated for glaucoma. Selectively blocks beta1-adrenergic receptors with little or no effect on beta2-receptors. Reduces IOP by reducing production of aqueous humor.

Adult

1-2 gtt in affected eye(s) bid; consider concomitant therapy if IOP is not at satisfactory level

Pediatric

Not established

May have additive systemic effects if patient is already on systemic beta-blockers

Documented hypersensitivity; bronchial asthma; severe chronic obstructive pulmonary disease; sinus bradycardia; second- and third-degree AV block; overt cardiac failure; cardiogenic shock

Pregnancy

C - Safety for use during pregnancy has not been established.

Precautions

Beta-blockade may potentiate muscle weakness consistent with myasthenic symptoms; product may have sulfites, which may cause hypersensitivity reactions in susceptible persons

Prostaglandin agonists

For reduction of IOP in patients intolerant to other IOP-lowering medications or who do not respond optimally to other IOP-lowering medications.


Travoprost ophthalmic solution (Travatan)

Prostaglandin F2-alpha analog. Selective FP prostanoid receptor agonist believed to reduce IOP by increasing uveoscleral outflow. Used to treat open-angle glaucoma or ocular hypertension.

Adult

1 gtt in affected eye(s) hs; not to exceed 1 dose/d

Pediatric

Not established

Documented hypersensitivity; signs of inflammation; pregnancy

Pregnancy

C - Safety for use during pregnancy has not been established.

Precautions

Commonly causes ocular hyperemia; may cause permanent increase in pigment to iris (ie, increases brown pigment) and eyelid; may increase eyelash growth; may cause bacterial keratitis; caution in uveitis or macular edema; do not instill if wearing contact lenses


Unoprostone ophthalmic solution (Rescula)

Prostaglandin F2-alpha analog. Selective FP prostanoid receptor agonist believed to reduce IOP by increasing uveoscleral outflow. Used to treat open-angle glaucoma or ocular hypertension.

Adult

Instill 1 gtt in affected eye(s) bid

Pediatric

Not established

Documented hypersensitivity; signs of inflammation

Pregnancy

C - Safety for use during pregnancy has not been established.

Precautions

Commonly causes ocular hyperemia; may cause permanent increase in pigment to iris (ie, increases brown pigment) and eyelid; may increase eyelash growth; may cause bacterial keratitis; caution in uveitis or macular edema; do not instill if wearing contact lenses


Bimatoprost ophthalmic solution (Lumigan)

A prostamide analogue with ocular hypotensive activity. Mimics the IOP-lowering activity of prostamides via the prostamide pathway. Used to reduce IOP in open-angle glaucoma or ocular hypertension.

Adult

Instill 1 gtt of 0.03% solution in affected eye(s) hs; not to exceed 1 dose/d

Pediatric

Not established

Documented hypersensitivity; signs of inflammation

Pregnancy

C - Safety for use during pregnancy has not been established.

Precautions

May cause permanent increase in pigment to iris (ie, increases brown pigment) and eyelid; may increase eyelash growth; may cause bacterial keratitis; caution in uveitis or macular edema; do not instill if wearing contact lenses


Latanoprost (Xalatan)

May decrease IOP by increasing outflow of aqueous humor.

Adult

1 gtt (1.5 mcg) in affected eye(s) qd in evening; higher frequency administrations may decrease effectiveness

Pediatric

Not established

Coadministration with eye drops containing the preservative thimerosal may reduce effects (administer at intervals of 5 min between applications)

Pregnancy

B - Usually safe but benefits must outweigh the risks.

Precautions

Do not administer while wearing contact lenses; may increase brown pigment in iris and gradually change eye color (unknown effect)

More on Glaucoma, Low Tension

Overview: Glaucoma, Low Tension
Differential Diagnoses & Workup: Glaucoma, Low Tension
Treatment & Medication: Glaucoma, Low Tension
Follow-up: Glaucoma, Low Tension
References
[ CLOSE WINDOW ]

References

  1. Abedin S, Simmons RJ, Grant WM. Progressive low-tension glaucoma: treatment to stop glaucomatous cupping and field loss when these progress despite normal intraocular pressure. Ophthalmology. Jan 1982;89(1):1-6. [Medline].

  2. Fraunfelder FT, Roy FH. Current Ocular Therapy. Philadelphia: WB Saunders;2000: 488-9.

  3. Hitchings RA. Low tension glaucoma--its place in modern glaucoma practice. Br J Ophthalmol. Aug 1992;76(8):494-6. [Medline].

  4. Netland PA, Chaturvedi N, Dreyer EB. Calcium channel blockers in the management of low-tension and open-angle glaucoma. Am J Ophthalmol. May 15 1993;115(5):608-13. [Medline].

  5. Stewart WC, Reid KK. Incidence of systemic and ocular disease that may mimic low-tension glaucoma. J Glaucoma. 1992;1:27-31.

  6. Werner E. Progressive normal-tension glaucoma. I. Analysis. J Glaucoma. Dec 1996;5(6):422-6. [Medline].

[ CLOSE WINDOW ]

Further Reading

[ CLOSE WINDOW ]

Keywords

LTG, low-pressure glaucoma, optic neuropathy, intraocular pressure, primary open-angle glaucoma, POAG

[ CLOSE WINDOW ]

Contributor Information and Disclosures

Author

Iqbal Ike K Ahmed, MD, FRCSC, Clinical Assistant Professor, Department of Ophthalmology, University of Utah
Iqbal Ike K Ahmed, MD, FRCSC is a member of the following medical societies: American Academy of Ophthalmology, American Society of Cataract and Refractive Surgery, Canadian Ophthalmological Society, and Ontario Medical Association
Disclosure: Nothing to disclose.

Coauthor(s)

Baseer U Khan, MD, Staff Physician, Department of Ophthalmology, University of Toronto, Canada
Baseer U Khan, MD is a member of the following medical societies: Canadian Ophthalmological Society
Disclosure: Nothing to disclose.

Khalid Hasanee, MD, Glaucoma and Anterior Segment Fellow, Department of Ophthalmology, University of Toronto
Khalid Hasanee, MD is a member of the following medical societies: Canadian Medical Association, Canadian Ophthalmological Society, and Ontario Medical Association
Disclosure: Nothing to disclose.

Medical Editor

Neil T Choplin, MD, Adjunct Clinical Professor, Department of Surgery, Section of Ophthalmology, Uniformed Services University of Health Sciences
Neil T Choplin, MD is a member of the following medical societies: American Academy of Ophthalmology, American Glaucoma Society, Association for Research in Vision and Ophthalmology, and California Medical Association
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Martin B Wax, MD, Clinical Professor, Department of Ophthalmology, University of Texas Southwestern Medical School; Vice President, Ophthalmology Research and Development, Head, Ophthalmology Discovery Research, Alcon Labs, Inc
Martin B Wax, MD is a member of the following medical societies: American Academy of Ophthalmology, American Glaucoma Society, and Society for Neuroscience
Disclosure: Alcon Labs Salary Employment

CME Editor

Lance L Brown, OD, MD, Ophthalmologist, Affiliated With Freeman Hospital and St John's Hospital, Regional Eye Center, Joplin, Missouri
Disclosure: Nothing to disclose.

Chief Editor

Hampton Roy Sr, MD, Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences
Hampton Roy Sr, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, and Pan-American Association of Ophthalmology
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.